MannKind | MNKD - Passifs Courants





Passifs Courants Changement Date
Adma Biologics USD 69.54M 13.05M 2025-12
BioCryst Pharmaceuticals USD 196.07M 5.83M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Insmed USD 468.87M 51.66M 2025-12
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
MacroGenics USD 43.11M 1.36M 2025-12
MannKind USD 171.03M 61.9M 2025-12
Merck USD 28.63B 2.59B 2025-09
Minerva Neurosciences USD 2.29M 381K 2025-12
Novavax USD 459.95M 30.08M 2025-12
Novo Nordisk DKK 32.79B 203.33B 2025-06
Pfizer USD 36.6B 1.13B 2025-09
Sanofi EUR 28.35B 3.76B 2025-12
Xencor USD 95.91M 9.42M 2025-12